April 04, 2025

First IgG4-RD Treatment Approved

A humanized monoclonal antibody that targets CD19+ B cells is first FDA-approved treatment for immunoglobulin G4–related disease, reducing flare risk and glucocorticoid use in clinical trials.

Conexiant

April 04, 2025

New Biomarker May Predict Alzheimer's Cognitive Decline

A novel CSF protein ratio, YWHAG:NPTX2, outperforms traditional biomarkers in predicting cognitive resilience vs progressive cognitive impairment in patients with Alzheimer's disease.

Conexiant

April 04, 2025

Post-COVID Diabetes Risk Higher in Unvaccinated

Compared with a historical cohort of patients hospitalized for influenza, those hospitalized for COVID-19 had a 45% higher post-acute type 2 diabetes risk during delta and a 56% higher risk during omicron.

Conexiant

April 04, 2025

Gram-Negative Infection: 7 vs 14 Days of Antibiotics

Mortality occurred in 12.8% of the patients in the 7-day group compared with 13.7% of those in the 14-day group.

Conexiant

April 03, 2025

Depemokimab Reduces Nasal Polyps, Obstruction in CRSwNP

Depemokimab significantly reduced nasal polyp scores and obstruction symptoms in patients with chronic rhinosinusitis in the ANCHOR-1 and ANCHOR-2 trials. The data support depemokimab as a twice-yearly treatment option, researchers reported.

Conexiant

April 02, 2025

New Antibody Lowers COVID-19 Cases in Trial

Sipavibart reduced symptomatic COVID-19 by 34.9% compared to standard treatment, but efficacy was only observed against non–Phe456Leu-containing variants, according to new phase 3 trial data.

Conexiant

April 02, 2025

FDA Approves Automated Latent TB Test

Revvity’s Auto-Pure 2400 platform for use with the T-SPOT.TB test to automate latent tuberculosis diagnostics was approved by the FDA.

Conexiant

April 01, 2025

FDA Approves Freeze-Dried Jynneos Vaccine

Bavarian Nordic’s freeze-dried Jynneos vaccine offers logistical advantages over the liquid-frozen version, supporting long-term U.S. stockpiling and public health preparedness.

Conexiant

April 01, 2025

Cemiplimab Effective for Advanced cSCC

Meta-analysis of 19 studies reveals promising 54.5% objective response rate and manageable safety profile for PD-1 inhibitor in treating advanced cutaneous squamous cell carcinoma.

Conexiant